Radiopharmaceutical Sciences in Oncology: Advances in Theranostics, Radionuclide Production, and AI
This Lancet Oncology Series paper surveys the current state of radiopharmaceutical sciences in oncology, covering developments in radiochemistry, novel radionuclide production, theranostic agent translation, and AI-assisted workflow optimisation. The authors highlight how these advances are driving global growth in therapeutic nuclear medicine while identifying key challenges including radionuclide supply chains, regulatory harmonisation, and equitable access.
The original study
Recent advances and impending challenges for the radiopharmaceutical sciences in oncology.
- Authors
- Lapi SE, Scott PJH, Scott AM, Windhorst AD, Zeglis BM, Abdel-Wahab M, et al.
- Journal
- The Lancet. Oncology
- Type
- Journal Article, Review
- PMID
- 38821098
Original abstract
This paper is the first of a Series on theranostics that summarises the current landscape of the radiopharmaceutical sciences as they pertain to oncology. In this Series paper, we describe exciting developments in radiochemistry and the production of radionuclides, the development and translation of theranostics, and the application of artificial intelligence to our field. These developments are catalysing growth in the use of radiopharmaceuticals to the benefit of patients worldwide. We also highlight some of the key issues to be addressed in the coming years to realise the full potential of radiopharmaceuticals to treat cancer.